Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies

Bone Marrow Transplantation

Volumn 18, Issue 2, 1996, Pages 347-353

  Couriel, D ^a   Canosa, J ^b   Engler, H ^b   Collins, A ^c   Dunbar, C ^a   Barrett, A J ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Allogeneic bone marrow transplantation; CMV; Interstitial pneumonitis; T cell depletion

Indexed keywords

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CYTOMEGALOVIRUS; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; T-LYMPHOCYTES; VIRUS ACTIVATION;

EID: 0029833010     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Meyers JD. Cytomegalovirus infection following marrow transplantation: risk, treatment, and prevention. Birth Defects 1984; 20: 101-107.
2. Goodrich JA, Boeckh M, Bowden R. Strategies for the prevention of Cytomegalovirus after marrow transplantation. Clin Infect Dis 1994; 19: 287-298.
3. Reed EC, Bowden RA, Dandliker PS et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783-788.
4. Goodrich JM, Zaia JA, Boeckh M et al. Ganciclovir strategies after marrow transplantation. Bone Marrow Transplant 1995; 15 (Suppl. 1): S156-S166.
5. Schmidt GM, Horak DA, Niland JC et al and The City of Hope-Stanford-Syntex CMV Study Group. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New Engl J Med 1991; 324: 1005-1011.
6. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
7. Rowe JM, Ciobanu N, Ascensaõ J et al and the Eastern Cooperative Oncology Group. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. Ann Intern Med 1994; 120: 143-158.
8. Bacigalupo A, van Lint MT, Tedone E et al. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant 1994; 13: 753-758.
9. Walter EJ, Greenberg PD, Gilbert MJ et al. Reconstruction of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New Engl J Med 1995; 333: 1038-1044.
10. Quinones RR, Gutierrez RH, Dinndorf PA et al. Extended-cycle elutriation to adjust T-cell content in HLA-disparate bone marrow transplantation. Blood 1993; 82: 307-317.
11. Couriel D, Cottier-Fox M, Burt RK et al. T-cell depleted marrow transplants with delayed lymphocyte add-back to prevent relapse in patients with leukemia and MDS. Blood 1994; 84 (Suppl. 1): 10 (Abstr. 1321).
12. Webster A, Blizzard B, Pillay D et al. Value of routine surveillance cultures for detection of CMV pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1993; 12: 477-481.
13. Stirk PR, Griffiths PD. Use of monoclonal antibodies for the diagnosis of cytomegalovirus infection by the detection of early antigenic flourescent foci (DEAFF) in cell culture. J Med Virol 1987; 21: 329-337.
14. Boeckh M, Bowden RA, Goodrich JM et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358-1364.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-481.
16. Przepiorka D, Ippoliti C, Panina A et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant 1994; 13: 461-464.
17. Herenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995; 15: 387-393.
18. Baciagalupo A, Tedone E, Isaza A et al. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality. Bone Marrow Transplant 1995; 16: 155-161.
19. Bortin MM, Ringdén O, Horowitz MM et al. Termporal relationship between the major complications of BMT for leukaemia. Bone Marrow Transplant 1989; 4: 339-344.
20. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
21. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373-1380.
22. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral disease. Annu Rev Immunol 1995; 13: 545-586.
23. Van den Berg AP, van Son WJ, Janssen RAJ et al. Recovery from cytomegalovirus infection is associated with activation of peripheral blood lymphocytes. J Infect Dis 1992; 166: 1228-1235.
24. Einsele H, Ehninger G, Steidle Fischer I et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672-1678.
25. Fries BC, Khaira D, Pepe MS, Torok-Storb B. Declining lymphocyte counts following cytomegalovirus (CMV) infection are associated with fatal CMV disease in bone marrow transplant patients. Exp Hematol 1993; 21: 1387-1392.
26. Thé TH, van der Ploeg M, van den Berg AP, et al. Direct detection of cytomegalovirus in peripheral blood leukocytes - a review of the antigenemia assay and polymerase chain reaction. Transplantation 1992; 54: 193-198.
27. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
28. De Clercq E. Antivirals for the treatment of herpevirus infections. J Antimicrob Chemother 1993; 32 (Suppl. A): 121-132.
29. Lalezari JP, Drew WL, Glutzer E et al. (S)-1-[3-Hydroxy-2 (phosphonylmethoxy) proplcytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995; 171: 788-796.
30. Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994; 343: 749-753.